1. Lonial, S, Weiss, BM, Usmani, SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016; 387: 1551–1560.
Google Scholar | Crossref | Medline | ISI2. Dimopoulos, MA, Oriol, A, Nahi, H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375: 1319–1331.
Google Scholar | Crossref | Medline | ISI3. Palumbo, A, Chanan-Khan, A, Weisel, K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375: 754–766.
Google Scholar | Crossref | Medline | ISI4. Dimopoulos, M, Quach, H, Mateos, MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 2020; 396: 186–197.
Google Scholar | Crossref | Medline5. Mateos, MV, Cavo, M, Blade, J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 2020; 395: 132–141.
Google Scholar | Crossref | Medline6. Facon, T, Kumar, S, Plesner, T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019; 380: 2104–2115.
Google Scholar | Crossref | Medline7. Moreau, P, Attal, M, Hulin, C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019; 394: 29–38.
Google Scholar | Crossref | Medline8. Voorhees, PM, Kaufman, JL, Laubach, JP, et al. Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Blood 2020; 136: 936–945.
Google Scholar | Crossref | Medline9. Landgren, O, Hultcrantz, M, Diamond, B, et al. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol 2021; 7: 862–868.
Google Scholar | Crossref | Medline10. Frerichs, KA, Bosman, PWC, Van Velzen, JF, et al. Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. Haematologica 2020; 105: E302–E306.
Google Scholar | Crossref | Medline11. Chng, WJ, Dispenzieri, A, Chim, CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014; 28: 269–277.
Google Scholar | Crossref | Medline12. Chari, A, Suvannasankha, A, Fay, JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017; 130: 974–981.
Google Scholar | Crossref | Medline13. Cohen, YC, Zada, M, Gatt, ME, et al. Kydar multicenter trial of quadruple regimen for induction resistant myeloma combined with translational single-cell analysis identifies potential drivers of advanced resistance, including novel immune checkpoints. Blood 2019; 134(Suppl. 1): 982–982.
Google Scholar | Crossref14. Van de Wyngaert, Z, Carpentier, B, Pascal, L, et al. Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population. Br J Haematol 2020; 188: e24–e27.
Google Scholar | Crossref | Medline15. Perry, DK, Burns, JM, Pollinger, HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2008; 9: 201–209.
Google Scholar | Crossref | Medline16. Gomez, AM, Willcox, N, Vrolix, K, et al. Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients. J Immunol 2014; 193: 1055–1063.
Google Scholar | Crossref | Medline | ISI17. Alexander, T, Sarfert, R, Klotsche, J, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 2015; 74: 1474–1478.
Google Scholar | Crossref | Medline | ISI18. Van De Donk, N . Predictive markers of high-grade or serious treatment-emergent infections with daratumumab-based regimens in Newly Diagnosed Multiple Myeloma (NDMM). Paper presented at the 62nd ASH Annual Meeting and Exposition, , San Diego Convention Center, San Diego, CA.
Google Scholar19. Nucci, M, Anaissie, E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009; 49: 1211–1225.
Google Scholar | Crossref | Medline | ISI20. Brioli, A, Klaus, M, Sayer, H, et al. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol 2019; 98: 713–722.
Google Scholar | Crossref | Medline21. Blanco, B, Pérez-Simón, JA, Sánchez-Abarca, LI, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006; 107: 3575–3583.
Google Scholar | Crossref | Medline22. Giles, AJ, Hutchinson, MKND, Sonnemann, HM, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer 2018; 6: 1–13.
Google Scholar | Crossref | Medline23. Ueda, M, Berger, M, Gale, RP, et al. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. Blood Rev 2018; 32: 106–115.
Google Scholar | Crossref | Medline24. Snowden, JA, Ahmedzai, SH, Ashcroft, J, et al. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 2011; 154: 76–103.
Google Scholar | Crossref | Medline | ISI25. Katz, U, Achiron, A, Sherer, Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6: 257–259.
Google Scholar | Crossref | Medline | ISI26. Chapel, HM, Lee, M, Hargreaves, R, et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet 1994; 343: 1059–1063.
Google Scholar | Crossref | Medline | ISI